Trial Profile
Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2024
Price :
$35
*
At a glance
- Drugs VSV-IFNbeta-NIS (Primary) ; Cemiplimab; Cyclophosphamide; Ipilimumab; Nivolumab; Ruxolitinib
- Indications Acute myeloid leukaemia; Anaplastic large cell lymphoma; B-cell lymphoma; Cutaneous T-cell lymphoma; Multiple myeloma; Mycosis fungoides; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions; First in man
- 06 Feb 2024 Number of treatment arms increased from 3 to 4 by the addition of Experimental: Group D (VSV-IFNbeta-NIS, ruxolitinib, cemiplimab) arm, thus adding Cemiplimab also to the treatment regimen.
- 12 Dec 2023 Results assessing the maximum tolerated dose of Vesicular Stomatitis Virus in patients with Relapsed or Refractory Multiple Myeloma, and TCL, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 01 Aug 2023 Planned End Date changed from 29 Dec 2023 to 1 Dec 2024.